Richards, Merrill & Peterson’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
BC
Richards, Merrill & Peterson's XBI Position: Q2 2025 in Review
Richards, Merrill & Peterson sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 100 shares — an estimated $8.11K sold.
Richards, Merrill & Peterson first reported a position in XBI in Q4 2024 and held it in 2 quarters. The position peaked at $9.01K in Q4 2024. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.
- Richards, Merrill & Peterson reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
- Richards, Merrill & Peterson sold 100 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $8.11K.
- Richards, Merrill & Peterson first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 2 quarters.
- Richards, Merrill & Peterson's State Street SPDR S&P Biotech ETF position peaked at $9.01K in Q4 2024.
- 625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.
Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.